Vol 9 Issue 7

CELL AND GENE THERAPY INSIGHTS

Vol 9 Issue 7

Cell and Gene Therapy Insights Vol 9 Issue 7

Download PDF

Featuring

Issue Spotlight: New horizons in immunotherapy
Driving the digitization of cell and gene therapy supply chains 2023
Other articles
Webinars

New horizons in immunotherapy

David Morrow

Guest Editor:

David Morrow, Scientific Programme Manager, Translational Medicine & Drug Development at EATRIS

Editorial

European research infrastructures join forces to provide innovative cancer research services across Europe—how can they support the cell and gene therapy developer?

European research infrastructures join forces to provide innovative cancer research services across Europe—how can they support the cell and gene therapy developer?

E Oldoni, P Carvajal-Vallejos, F Bietrix et al.

Expert Insight

Harnessing chimeric antigen receptor (CAR)-T cells as a potential treatment for Alzheimer’s disease

Harnessing chimeric antigen receptor (CAR)-T cells as a potential treatment for Alzheimer’s disease

Lauren Sarko, Krishanu Saha

14 September 2023

Interview

Developing universal AAV immuno-gene therapy for oncology

Developing universal AAV immuno-gene therapy for oncology

Does synthetic biology hold the key to unlocking solid tumors for cell and gene therapy?

Does synthetic biology hold the key to unlocking solid tumors for cell and gene therapy?

Rearming the immune system with personalized allogeneic CAR-T cell therapy

Rearming the immune system with personalized allogeneic CAR-T cell therapy

Increasing patient access to cellular immunotherapy through RNA gene writing

Increasing patient access to cellular immunotherapy through RNA gene writing

Madhusudan Peshwa

Viewpoint

iNKT cells for allogeneic cell therapy

iNKT cells for allogeneic cell therapy

Eleni Chantzoura, Paul Ibbett

Driving the digitization of cell and gene therapy supply chains 2023

Commentary

Cell and gene therapy commercial off-the-shelf software components

Cell and gene therapy commercial off-the-shelf software components

Journal articles

Innovator Insight

Future-proof your AAV process with a complete producer cell line

Future-proof your AAV process with a complete producer cell line

Dovile Gruzdyte

Addressing regulatory guidance for HEK293 cells & AAV-based therapeutics manufacturing

Addressing regulatory guidance for HEK293 cells & AAV-based therapeutics manufacturing

Overcoming upstream & downstream process barriers for large-scale AAV production

Overcoming upstream & downstream process barriers for large-scale AAV production

Betty Woo, Jonathan Zmuda

8 September 2023

Interview

How a new generation of FDA reviewers can meet the future demands of cell and gene therapy

How a new generation of FDA reviewers can meet the future demands of cell and gene therapy

FastFacts

Developing oligonucleotide therapeutics with confidence

Developing oligonucleotide therapeutics with confidence

Viewpoint

Leading a gene therapy team to market approval success

Leading a gene therapy team to market approval success

Infographic

Residual DNA testing: Homebrew vs off-the-shelf solutions: INFOGRAPHIC

Residual DNA testing: Homebrew vs off-the-shelf solutions: INFOGRAPHIC

Webinar Digest

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Pim Hermans, Frank Detmers

Poster

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

M Brewer, A Cockroft, C Fuentes et al.

AAV vectors in a spin: zonal ultracentrifugation as an effective, automated and scalable downstream processing methodology

AAV vectors in a spin: zonal ultracentrifugation as an effective, automated and scalable downstream processing methodology

Sandra Meriño, Seth Brittle

Establishing the standards of operational excellence to manufacture commercial cell therapies

Establishing the standards of operational excellence to manufacture commercial cell therapies

Hui Zheng, Melanie Mansbach

Allogeneic cell therapy production trends: driving tomorrow’s success

Allogeneic cell therapy production trends: driving tomorrow’s success

Tom Bongiorno

Expand your T cell manufacturing capacities in an automated, closed system to shorten your production time

Expand your T cell manufacturing capacities in an automated, closed system to shorten your production time

Sophia Lollies, Ian Johnston